Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory <i>FLT3</i>-Mutated AML
Most Cited Paper
in Acute Myeloid Leukemia Research
18 Months Post-Publication
Class of 2026
“Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory <i>FLT3</i>-Mutated AML”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
Azacitidine · Venetoclax · gilteritinib · FLT3-mutated AML · FLT3-internal tandem duplication · FLT3 internal tandem duplication (FLT3-ITD) · oral FLT3 inhibitor · Newly diagnosed acute myeloid leukemia · Relapsed/refractory acute myeloid leukemia · Complete remission (CR) · Complete remission with incomplete hematologic recovery (CRi) · CRi · Measurable residual disease (MRD) · MRD negativity · relapse-free survival · Overall survival · morphologic leukemia-free state · myelosuppression · maximum tolerated dose · phase I/II trial
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Acute Myeloid Leukemia Research Papers, Class of 2026. https://pri.pepkio.com/top-papers/acute-myeloid-leukemia-research/2026. Accessed 2026-07-31. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459